GW572016 In Patients With Advanced Or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2006-12-20
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and safety of GW572016 in patients with
refractory breast cancer and consists of two cohorts of patients. Patients in Cohort A must
have ErbB2 overexpressing tumors while patients in Cohort B must have non-ErbB2
overexpressing tumors. Patients eligible for this study must have advanced metastatic breast
cancer who have previously received treatment with anthracycline and taxane.